GMMA-based vaccine candidates against invasive nontyphoidal salmonellosis elicit bactericidal antibodies against a panel of epidemiologically relevant Salmonellae

GMMA-based vaccine candidates against invasive nontyphoidal salmonellosis elicit bactericidal antibodies against a panel of epidemiologically relevant Salmonellae

Systemic disease caused by nontyphoidal Salmonella (NTS) represents a major cause of death and morbidity, especially in young children in sub-Saharan Africa. No licensed vaccine is yet available, and an increase in antimicrobial resistance makes the development of a vaccine a global health priority....

Full description

Saved in:
Bibliographic Details
Main Authors: Daniele De Simone, Marika Pinto, Maria Grazia Aruta, Marta Benincasa, Martina Carducci, Roberta Di Benedetto, Francesco Citiulo, Miren Iturriza, Elli Mylona, Stephen Baker, Mariagrazia Pizza, Carlo Giannelli, Francesca Mancini, Rocío Canals, Omar Rossi
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Immunology
Subjects:
GMMA
iNTS
Salmonella
SBA
vaccine
O-antigen
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1610067/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic disease caused by nontyphoidal Salmonella (NTS) represents a major cause of death and morbidity, especially in young children in sub-Saharan Africa. No licensed vaccine is yet available, and an increase in antimicrobial resistance makes the development of a vaccine a global health priority. We are developing a bivalent formulation of Salmonella Typhimurium and Salmonella Enteritidis generalized modules for membrane antigens (GMMA)–based vaccine (iNTS-GMMA) and a trivalent formulation (iNTS-TCV) in which iNTS-GMMA is combined with the WHO-prequalified TYPHIBEV (Biological E, India) vaccine to prevent typhoid fever in addition to invasive NTS (iNTS) disease. Here, we measured the ability of antibodies induced by iNTS-GMMA and iNTS-TCV formulations in mice and rabbits to kill a broad panel of Salmonella in vitro in a complement-mediated fashion. These organisms include those causing invasive disease in Africa and Southeast Asia, global representatives causing gastroenteritis and other S. enterica serovars in addition to S. Typhimurium and S. Enteritidis. We characterized the O-antigen of the panel of isolates and demonstrated the sera functionality in both animal species against all isolates, providing evidence of the potential broad coverage of both GMMA-based formulations, which are currently undergoing testing in Phase I/II clinical trials.
ISSN:1664-3224

Similar Items